Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?

Answer from: Radiation Oncologist at Community Practice

Given that there are no cancer control outcomes (local control) and the follow-up is short from EUROPA, I would say no.However, I do talk to patients eligible for omission of RT about this option and the data that are available. while it's an old trial, B21 showed RT drastically reduced LR as compar...

Comments

Radiation Oncologist at West Virginia University
Data now demonstrates that 5 years (or more) of ET...

Radiation Oncologist at Firelands Regional Medical Center
Agree!

Radiation Oncologist at RadiantCare
Table 3 in the linked paper does report IBTR, LRR,...

Radiation Oncologist at Allegheny Health Network, Pittsburgh
These are quite short (median follow-up around 2 y...

Answer from: Radiation Oncologist at Community Practice

How do you ask a woman to be the last woman to suffer for an unlikely, non-lethal recurrence? For women with low-risk breast cancer, endocrine therapy does not improve survival and is less effective at decreasing recurrences—we saw this in NSABP B-21. Yet it causes years of suffering: art...

Please select the option that best describes you:

Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?

Related Questions